Exencial Wealth Advisors, LLC Fate Therapeutics Inc Transaction History

Exencial Wealth Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$29.67 - $60.28 $127,729 - $259,505	-4,305 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$59.27 - $95.73 $1,778 - $2,871	30 Added 0.7%	4,305 $255,000
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $11,768 - $16,191	-175 Reduced 3.93%	4,275 $371,000
Q1 2021 May 06, 2021	SELL	$72.16 - $117.4 $126,280 - $205,450	-1,750 Reduced 28.23%	4,450 $367,000
Q4 2020 Feb 11, 2021	SELL	$38.09 - $100.95 $19,045 - $50,475	-500 Reduced 7.46%	6,200 $564,000
Q2 2020 Aug 17, 2020	BUY	$20.21 - $35.23 $135,407 - $236,040	6,700 New	6,700 $230,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Exencial Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Exencial Wealth Advisors, LLC with notifications on news.